Patents Assigned to Synerkine Pharma B.V.
  • Fusion protein comprising IL13
    Patent number: 12365713
    Abstract: The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and/or or neurodegeneration.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: July 22, 2025
    Assignee: Synerkine Pharma B.V.
    Inventors: Niels Eijkelkamp, Cornelis Erik Hack, Judith Prado Sanchez, Jelena Popov-Čeleketić, Sabine Versteeg
  • Fusion protein comprising IL13
    Patent number: 11312757
    Abstract: The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and/or or neurodegeneration.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: April 26, 2022
    Assignee: Synerkine Pharma B.V.
    Inventors: Niels Eijkelkamp, Cornelis Erik Hack, Judith Prado Sanchez, Jelena Popov-{hacek over (C)}eleketić, Sabine Versteeg
  • Fusion protein comprising IL-4 and IL-10
    Patent number: 10981964
    Abstract: The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: April 20, 2021
    Assignee: Synerkine Pharma B.V.
    Inventors: Joel Adrianus Gijsbert Van Roon, Sarita Aimee Yvonne Hartgring, Cornelis Erik Hack, Christina Louws, Floris Paulus Jacobus Gerardus Lafeber
  • Methods of treatment with a fusion protein comprising IL-4 and IL-10
    Patent number: 10851143
    Abstract: The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: December 1, 2020
    Assignee: Synerkine Pharma B.V.
    Inventors: Joel Adrianus Gijsbert Van Roon, Sarita Aimee Yvonne Hartgring, Cornelis Erik Hack, Christina Louws, Floris Paulus Jacobus Gerardus Lafeber